$BBIO · BridgeBio Pharma, Inc.

BridgeBio Pharma announced FDA acceptance of its NDA for oral infigratinib for children with achondroplasia, granted Priority Review with a PDUFA target action date of February 4, 2027. The submission is supported by PROPEL 3 Phase 3 data showing a +2.10 cm/yr annualized height velocity treatment effect (p<0.0001) and the first statistically significant improvement in body proportionality in an achondroplasia trial. BridgeBio plans an EMA submission in Q4 2026 and anticipates U.S. launch upon approval.

Markets closed — no regular-session reaction yet; extended-hours move not captured here. The $12.88B market cap reflects substantial expectations already priced in for the achondroplasia franchise.

Oral infigratinib would be the first oral therapy for achondroplasia, supported by the strongest Phase 3 efficacy data reported to date, including unique proportionality and arm-span benefits.

This filing positions BridgeBio to compete directly with BioMarin's Voxzogo (injectable, approved 2021) in the achondroplasia market. An oral option with broader efficacy data on proportionality and functional endpoints could reshape the treatment landscape for ~10,000 addressable children in the U.

FDA may not approve oral infigratinib by the February 4, 2027 PDUFA date or at all; the EMA submission planned for Q4 2026 may be delayed; exploratory endpoint trends (sleep apnea, otitis media) may not translate into label claims or long-term clinical benefits.